Daten einiger GBG Forschungsprojekte werden beim ESMO 2019 vom 27. September bis 1. Oktober in Barcelona vorgestellt.
Mehr ...Data from two similar randomized phase III trials (LEA GBG51 and CALGB 40503) comparing the efficacy of standard ET versus experimental ET plus bevacizumab as first-line treatment for HR-positive MBC have been published in the European Journal of Cancer
Mehr ...We are glad to inform you that the results of a pooled analysis evaluating fatal events during GBG led breast cancer trials have been published in the Breast Cancer
Mehr ...Fortbildungsveranstaltung „Behandlung mit Checkpoint-Inihibitoren“ der GBG und des BreastNet Rhein Main am 27. August 2019 von 17:00 – 20:00 Uhr in Frankfurt
Mehr ...GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440
+49 6102 7480-0 | nfGBGd